Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Name: Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
License: Public Domain

Insel Gruppe AG, University Hospital Bern

ClinicalTrials.gov · Datasets · License: Public Domain

muscle-invasive bladder cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 180379
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.